Cited by 1,063Receptor Mechanisms and SignalingNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

Open access

Jeffrey Conn, P., Christopoulos, Arthur, Lindsley, Craig W.·2009·Nature Reviews Drug Discovery

DOI 10.1038/nrd2760PMC PMC2907734

Open this paper in CoChat — free account

Abstract

Despite G-protein-coupled receptors (GPCRs) being among the most fruitful targets for marketed drugs, intense discovery efforts for several GPCR subtypes have failed to deliver selective drug candidates. Historically, drug discovery programmes for GPCR ligands have been dominated by efforts to develop agonists and antagonists that act at orthosteric sites for endogenous ligands. However, in recent years, there have been tremendous advances in the discovery of novel ligands for GPCRs that act at allosteric sites to regulate receptor function. These compounds provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurological human disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrd2760

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J. (1997) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,083
The Ecology of Freshwater Phytoplankton.
Jones, R. I., & REYNOLDS, C. S. (1985) · Journal of Ecology · doi:10.2307/2260522 · Cited by 2,817
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
G Protein-coupled Receptors
Ji, T. H., Grossmann, M., & Ji, I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17299 · Cited by 1,281
Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity
Dorr, P. K., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M. J., Mori, J., Rickett, G., Smith‐Burchnell, C., Napier, C. M., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,154
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B. K., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,131
Self-citation
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 1,106
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006

Flagged first, then by citations

Show all 139 references

Research works printed but not linked: 2

Swanson, C. J., Bures, M., Johnson, M. P., Linden, A. M., Monn, J. A. & Schoepp, D. D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev. Drug Discov. 4, 131–144 (2005). · DOI · Paper page
Baez, M. et al. Molecular mapping of a subtype selective site for positive allosteric modulation of the mGlu2 receptor. Neuropharmacol. Abstr. 43, 274–275 (2002).

Sorted by citations

Items 201–300 of 1,000

Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities
Khurana, L., Mackie, K., Piomelli, D., & Kendall, D. A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.018 · Cited by 79
GPCRs: The most promiscuous druggable receptor of the mankind
Alhosaini, K. A., Azhar, A., Alonazi, A. S., & Al-Zoghaibi, F. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.04.015 · Cited by 86
Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression
Campo, B., Kalinichev, M., Lambeng, N., Yacoubi, M. E., Royer-Urios, I., Schneider, M. P., Legrand, C., Parron, D., Girard, F., Bessif, A., et al. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.627485 · Cited by 80
The sweet taste of true synergy: positive allosteric modulation of the human sweet taste receptor
Servant, G., Tachdjian, C., Li, X., & Karanewsky, D. S. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.007 · Cited by 80
Positive Allosteric Modulators of Type 5 Metabotropic Glutamate Receptors (mGluR5) and Their Therapeutic Potential for the Treatment of CNS Disorders
Cleva, R. M., & Olive, M. F. (2011) · Molecules · doi:10.3390/molecules16032097 · Cited by 77
Update 1 of: Computational Modeling Approaches to Structure–Function Analysis of G Protein-Coupled Receptors
Fanelli, F., & Benedetti, P. G. D. (2011) · Chemical Reviews · doi:10.1021/cr100437t · Cited by 77
A Novel Metabotropic Glutamate Receptor 5 Positive Allosteric Modulator Acts at a Unique Site and Confers Stimulus Bias to mGlu5 Signaling
Noetzel, M. J., Gregory, K. J., Vinson, P. N., Manka, J. T., Stauffer, S. R., Lindsley, C. W., Niswender, C. M., Xiang, Z., & Conn, P. J. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.082891 · Cited by 77
Self-citation
Muscarinic Antagonist Control of Myopia: Evidence for M 4 and M 1 Receptor-Based Pathways in the Inhibition of Experimentally-Induced Axial Myopia in the Tree Shrew
Arumugam, B., & McBrien, N. A. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9943 · Cited by 77
Allosteric coupling and biased agonism in G protein‐coupled receptors
Böck, A., & Bermúdez, M. (2021) · FEBS Journal · doi:10.1111/febs.15783 · Cited by 75
Moonlighting Adenosine Deaminase: A Target Protein for Drug Development
Cortés, A., Gracia, E., Moreno, E., Mallol, J., Lluís, C., Canela, E. I., & Casadó, V. (2014) · Medicinal Research Reviews · doi:10.1002/med.21324 · Cited by 77
mGlu5negative allosteric modulators: a patent review (2013 - 2016)
Emmitte, K. A. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1280466 · Cited by 77
Exploring and exploiting allostery: Models, evolution, and drug targeting
Peracchi, A., & Mozzarelli, A. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.10.008 · Cited by 76
Identification of the First Synthetic Allosteric Modulator of the CB2Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief
Gado, F., Mannelli, L. D. C., Lucarini, E., Bertini, S., Cappelli, E., Digiacomo, M., Stevenson, L., Macchia, M., Tuccinardi, T., Ghelardini, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00368 · Cited by 80
Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential
Geoffroy, C., Paoletti, P., & Mony, L. (2021) · The Journal of Physiology · doi:10.1113/jp280875 · Cited by 73
Allosteric modulation of G protein-coupled receptor signaling
Shen, S., Zhao, C. S., Wu, C., Sun, S., Li, Z., Yan, W. X., & Shao, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137604 · Cited by 80
3,5-Diphenylpent-2-enoic Acids as Allosteric Activators of the Protein Kinase PDK1: Structure−Activity Relationships and Thermodynamic Characterization of Binding as Paradigms for PIF-Binding Pocket-Targeting Compounds†PDB code of 2Z with PDK1: 3HRF.
Stroba, A., Schaeffer, F., Hindie, V., Lopez-Garcia, L. A., Adrian, I., Fröhner, W., Hartmann, R. W., Biondi, R. M., & Engel, M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9001499 · Cited by 75
Development of Dual PLD1/2 and PLD2 Selective Inhibitors from a Common 1,3,8-Triazaspiro[4.5]decane Core: Discovery of ML298 and ML299 That Decrease Invasive Migration in U87-MG Glioblastoma Cells
O’Reilly, M. C., Scott, S. A., Brown, K. A., Oguin, T. H., Thomas, P. G., Daniels, J. S., Morrison, R. D., Brown, H. A., & Lindsley, C. W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301782e · Cited by 75
Self-citation
Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
Quambusch, L., Landel, I., Depta, L., Weisner, J., Uhlenbrock, N., Müller, M. P., Glanemann, F., Althoff, K., Siveke, J. T., & Rauh, D. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909857 · Cited by 75
Broad-spectrum amino acid-sensing class C G-protein coupled receptors: Molecular mechanisms, physiological significance and options for drug development
Conigrave, A. D., & Hampson, D. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.007 · Cited by 74
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Coyle, J. T., Balu, D. T., Benneyworth, M. A., Basu, A. C., & Roseman, A. S. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jcoyle · Cited by 75
Discovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone Receptors
Nataraja, S. G., Yu, H. N., & Palmer, S. S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00142 · Cited by 72
Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor
Tresadern, G., Cid, J. M., Macdonald, G. J., Vega, J. A., de Lucas, A. I., Molina, A. G., Matesanz, E., Linares, M. L., Oehlrich, D., Lavreysen, H., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.008 · Cited by 73
Dances with black widow spiders: Dysregulation of glutamate signalling enters centre stage in ADHD
Lesch, K., Merker, S., Reif, A., & Novak, M. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.013 · Cited by 76
Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA
Scarr, E., Craig, J. M., Cairns, M. J., Seo, M. S., Galati, J. C., Beveridge, N. J., Gibbons, A. S., Juzva, S., Weinrich, B., Parkinson-Bates, M., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.3 · Cited by 72
Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
Noetzel, M. J., Jones, C. K., & Conn, P. J. (2012) · PubMed · Cited by 70
Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders
Moehle, M. S., & Conn, P. J. (2019) · Movement Disorders · doi:10.1002/mds.27740 · Cited by 70
Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site
Liu, Z., Li, Y., Chen, H., Lai, H., Wang, P., Wu, S., Wold, E. A., Leonard, P. G., Joseph, S., Hu, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01851 · Cited by 70
Neuroprotective effects of metabotropic glutamate receptor group II and III activators against MPP(+)-induced cell death in human neuroblastoma SH-SY5Y cells: The impact of cell differentiation state
Jantas, D., Gręda, A., Gołda, S., Korostyński, M., Grygier, B., Roman, A., Pilc, A., & Lasoń, W. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.019 · Cited by 69
Homology modeling of G-protein-coupled receptors with X-ray structures on the rise.
Yarnitzky, T., Levit, A., & Niv, M. Y. (2010) · PubMed · Cited by 70
Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases
Coskuner‐Weber, O., Mirzanli, O., & Uversky, V. N. (2022) · Biophysical Reviews · doi:10.1007/s12551-022-00968-0 · Cited by 70
Quinolizidinone Carboxylic Acids as CNS Penetrant, Selective M1 Allosteric Muscarinic Receptor Modulators
Kuduk, S. D., Chang, R. K., Marco, C. N. D., Ray, W. J., Ma, L., Wittmann, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., Hartman, G. D., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100095k · Cited by 69
Allosteric Modulation of a Cannabinoid G Protein-coupled Receptor
Shore, D. M., Baillie, G. L., Hurst, D. P., Navas, F., Seltzman, H. H., Marcu, J. P., Abood, M. E., Ross, R. A., & Reggio, P. H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.478495 · Cited by 69
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
The luminescent HiBiT peptide enables selective quantitation of G protein–coupled receptor ligand engagement and internalization in living cells
Boursier, M. E., Levin, S., Zimmerman, K., Machleidt, T., Hurst, R., Butler, B. L., Eggers, C. T., Kirkland, T. A., Wood, K. V., & Ohana, R. F. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011952 · Cited by 71
Impact of species variability and ‘probe‐dependence’ on the detection andin vivovalidation of allosteric modulation at the M4muscarinic acetylcholine receptor
Suratman, S., Leach, K., Sexton, P. M., Felder, C. C., Loiacono, R. E., & Christopoulos, A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01184.x · Cited by 68
Self-citation
The antipsychotic potential of muscarinic allosteric modulation
Bridges, T. M., Lebois, E. P., Hopkins, C. R., Wood, M. R., Jones, C. K., Conn, P. J., & Lindsley, C. W. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.4.1416977 · Cited by 68
Self-citation
A Fluorescence Resonance Energy Transfer-based M2 Muscarinic Receptor Sensor Reveals Rapid Kinetics of Allosteric Modulation
Maier‐Peuschel, M., Frölich, N., Dees, C., Hommers, L. G., Hoffmann, C., Nikolaev, V. O., & Lohse, M. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.098517 · Cited by 68
Classics in Chemical Neuroscience: Levodopa
Whitfield, A. C., Moore, B. T., & Daniels, R. N. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5001759 · Cited by 68
Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM
Bridges, T. M., Kennedy, J. P., Cho, H. P., Breininger, M. L., Gentry, P. R., Hopkins, C. R., Conn, P. J., & Lindsley, C. W. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.089 · Cited by 67
Self-citation
Mglur4-Positive Allosteric Modulation as Potential Treatment for Parkinson’s Disease
Hopkins, C. R., Lindsley, C. W., & Niswender, C. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.38 · Cited by 67
Self-citation
Positive allosteric modulation of M 1 and M 4 muscarinic receptors as potential therapeutic treatments for schizophrenia
Yohn, S. E., & Conn, P. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.012 · Cited by 66
PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?
Kenakin, T., & Strachan, R. T. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.05.001 · Cited by 67
Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator
Meguro, Y., Miyano, K., Hirayama, S., Yoshida, Y., Ishibashi, N., Ogino, T., Fujii, Y., Manabe, S., Eto, M., Nonaka, M., et al. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.04.002 · Cited by 68
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): The development of ML169, an MLPCN probe
Reid, P. R., Bridges, T. M., Sheffler, D. J., Cho, H. P., Lewis, L. M., Days, E., Daniels, J. S., Jones, C. K., Niswender, C. M., Weaver, C. D., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.015 · Cited by 66
Self-citation
Muscarinic Receptors as Model Targets and Antitargets for Structure-Based Ligand Discovery
Kruse, A. C., Weiss, D. R., Rossi, M., Hu, J., Hu, K., Eitel, K., Gmeiner, P., Wess, J., Kobilka, B. K., & Shoichet, B. K. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.087551 · Cited by 69
Allosteric modulators enhance agonist efficacy by increasing the residence time of a GPCR in the active state
Cao, A.-M., Quast, R. B., Fatemi, F., Rondard, P., Pin, J., & Margeat, E. (2021) · Nature Communications · doi:10.1038/s41467-021-25620-5 · Cited by 68
Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: Possible implications for the pharmacotherapy of autism spectrum disorders
Burket, J. A., Herndon, A. L., Winebarger, E. E., Jacome, L. F., & Deutsch, S. I. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.08.001 · Cited by 65
Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M1 Muscarinic Acetylcholine Receptor
Avlani, V. A., Langmead, C. J., Guida, E., Wood, M. D., Tehan, B. G., Herdon, H. J., Watson, J. M., Sexton, P. M., & Christopoulos, A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064345 · Cited by 65
Self-citation
Allo-Network Drugs: Extension of the Allosteric Drug Concept to Protein- Protein Interaction and Signaling Networks
Szilágyi, A., Nussinov, R., & Csermely, P. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313010007 · Cited by 65
Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment
Ellaithy, A., Younkin, J., González‐Maeso, J., & Logothetis, D. E. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.06.002 · Cited by 64
Allostery in GPCRs: ‘MWC’ revisited
Canals, M., Sexton, P. M., & Christopoulos, A. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.08.005 · Cited by 65
Self-citation
When simple agonism is not enough: Emerging modalities of GPCR ligands
Smith, N. J., Bennett, K. A., & Milligan, G. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.07.009 · Cited by 64
Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse, and Parkinson’s Disease
Dencker, D., Thomsen, M., Wörtwein, G., Weikop, P., Cui, Y., Jeon, J., Wess, J., & Fink‐Jensen, A. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200110q · Cited by 63
Unraveling Hidden Regulatory Sites in Structurally Homologous Metalloproteases
Udi, Y., Fragai, M., Grossman, M., Mitternacht, S., Arad‐Yellin, R., Calderone, V., Melikian, M., Toccafondi, M., Berezovsky, I. N., Luchinat, C., et al. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.04.009 · Cited by 64
Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development
Wold, E. A., Wild, C., Cunningham, K. A., & Zhou, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190709101449 · Cited by 65
Symmetric activation and modulation of the human calcium-sensing receptor
Park, J., Zuo, H., Frangaj, A., Fu, Z., Yen, L. Y., Zhang, Z., Mosyak, L., Slavkovich, V. N., Liu, J., Ray, K. M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2115849118 · Cited by 63
Discovery, Synthesis, and Structure–Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4) with Oral Efficacy in an Antiparkinsonian Animal Model
Jones, C. K., Engers, D. W., Thompson, A. D., Field, J. R., Blobaum, A. L., Lindsley, S. R., Zhou, Y., Gogliotti, R. D., Jadhav, S. B., Zamorano, R., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200956q · Cited by 63
Self-citation
Discovery of a Selective Allosteric M1Receptor Modulator with Suitable Development Properties Based on a Quinolizidinone Carboxylic Acid Scaffold
Kuduk, S. D., Chang, R. K., Marco, C. N. D., Pitts, D. R., Greshock, T. J., Ma, L., Wittmann, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200400m · Cited by 63
Pharmacological Characterization of JNJ-40068782, a New Potent, Selective, and Systemically Active Positive Allosteric Modulator of the mGlu2 Receptor and Its Radioligand [3H]JNJ-40068782
Lavreysen, H., Langlois, X., Ahnaou, A., Drinkenburg, W. H. I. M., Riele, P. T., Biesmans, I., der Linden, I. V., Peeters, L., Megens, A. A. H. P., Wintmolders, C., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204990 · Cited by 63
Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s)
Kulkarni, P. M., Kulkarni, A., Korde, A., Tichkule, R. B., Laprairie, R. B., Denovan‐Wright, E. M., Zhou, H., Janero, D. R., Zvonok, N., Makriyannis, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01303 · Cited by 64
Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation
Mazzitelli, M., Palazzo, E., Maione, S., & Neugebauer, V. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00383 · Cited by 67
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
From Engrams to Pathologies of the Brain
Denny, C. A., Lebois, E. P., & Ramirez, S. (2017) · Frontiers in Neural Circuits · doi:10.3389/fncir.2017.00023 · Cited by 65
In vivo multiplex imaging of dynamic neurochemical networks with designed far-red dopamine sensors
Zheng, Y. R., Cai, R., Wang, K., Zhang, J., Zhuo, Y., Dong, H., Zhang, Y., Wang, Y., Deng, F., Ji, E., et al. (2025) · Science · doi:10.1126/science.adt7705 · Cited by 69
Discovery and Cardioprotective Effects of the First Non-Peptide Agonists of the G Protein-Coupled Prokineticin Receptor-1
Gasser, A., Brogi, S., Urayama, K., Nishi, T., Kurose, H., Tafi, A., Ribeiro, N., Désaubry, L., & Nebigil, C. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121027 · Cited by 68
Novel Selective Allosteric and Bitopic Ligands for the S1P3 Receptor
Jo, E., Bhhatarai, B., Repetto, E., Guerrero, M. A., Riley, S., Brown, S. J., Kohno, Y., Roberts, E., Schürer, S. C., & Rosen, H. (2012) · ACS Chemical Biology · doi:10.1021/cb300392z · Cited by 62
Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders
Digby, G. J., Shirey-Rice, J. K., & Conn, P. J. (2010) · Molecular BioSystems · doi:10.1039/c002938f · Cited by 62
Allosteric modulators of rhodopsin-like G protein-coupled receptors: Opportunities in drug development
Müller, C. E., Schiedel, A. C., & Baqi, Y. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.06.002 · Cited by 62
Molecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor
Abdul‐Ridha, A., López, L., Keov, P., Thal, D. M., Mistry, S. N., Sexton, P. M., Lane, J. R., Canals, M., & Christopoulos, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.539080 · Cited by 63
Self-citation
Design of Peptide and Peptidomimetic Ligands with Novel Pharmacological Activity Profiles
Hruby, V. J., & Cai, M. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100456 · Cited by 61
Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70)
Li, X., Shao, H., Taylor, I. R., & Gestwicki, J. E. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160413140911 · Cited by 60
Pharmacological Chaperones for Misfolded Gonadotropin-Releasing Hormone Receptors
Conn, P. M., & Ulloa‐Aguirre, A. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385952-5.00008-7 · Cited by 64
Group II metabotropic glutamate receptors and schizophrenia
Moreno, J. L., Sealfon, S. C., & González‐Maeso, J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0130-3 · Cited by 61
The GABAB Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats
Augier, E., Dulman, R. S., Damadzic, R., Pilling, A., Hamilton, J. P., & Heilig, M. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.53 · Cited by 61
G protein-coupled receptors in acquired epilepsy: Druggability and translatability
Yu, Y., Nguyen, D. T., & Jiang, J. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101682 · Cited by 62
A practical guide to secondary pharmacology in drug discovery
Jenkinson, S. G., Schmidt, F., Ribeiro, L. R., Delaunois, A. G., & Valentin, J. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106869 · Cited by 64
GLOW: A Workflow Integrating Gaussian-Accelerated Molecular Dynamics and Deep Learning for Free Energy Profiling
Do, H. N., Wang, J., Bhattarai, A., & Miao, Y. (2022) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c01055 · Cited by 57
Regulation of neuronal chloride homeostasis by neuromodulators
Mahadevan, V., & Woodin, M. A. (2016) · The Journal of Physiology · doi:10.1113/jp271593 · Cited by 61
Synthesis and Characterization of Novel 2-Amino-3-benzoylthiophene Derivatives as Biased Allosteric Agonists and Modulators of the Adenosine A1Receptor
Valant, C., Aurelio, L., Devine, S. M., Ashton, T. D., White, J. M., Sexton, P. M., Christopoulos, A., & Scammells, P. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201600e · Cited by 60
Self-citation
The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia
Stansley, B. J., & Conn, P. J. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.02.003 · Cited by 60
mGlu5negative allosteric modulators: a patent review (2010 – 2012)
Emmitte, K. A. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.760544 · Cited by 59
Metabotropic Glutamate 7 Receptor Subtype Modulates Motor Symptoms in Rodent Models of Parkinson's Disease
Greco, B., Lopez, S., van der Putten, H., Flor, P. J., & Amalric, M. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162115 · Cited by 59
Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu5)
Stauffer, S. R. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn2000519 · Cited by 59
Direct and Propagated Effects of Small Molecules on Protein–Protein Interaction Networks
Cesa, L. C., Mapp, A. K., & Gestwicki, J. E. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00119 · Cited by 63
Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1 H )-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor
Cid, J. M., Tresadern, G., Duvey, G., Lütjens, R., Finn, T., Rocher, J., Poli, S. M., Vega, J. A., de Lucas, A. I., Matesanz, E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500496m · Cited by 58
Update on GPCR-based targets for the development of novel antidepressants
Mantas, I., Saarinen, M., Xu, Q., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01040-1 · Cited by 61
The state of the art in secondary pharmacology and its impact on the safety of new medicines
Brennan, R., Jenkinson, S. G., Brown, A. J., Delaunois, A. G., Dumotier, B. M., Pannirselvam, M., Rao, M., Ribeiro, L. R., Schmidt, F., Sibony, A., et al. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00942-3 · Cited by 61
Discovery of (R)-(2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu3 Selective and CNS Penetrant Negative Allosteric Modulator (NAM)
Wenthur, C. J., Morrison, R. D., Felts, A. S., Smith, K. A., Engers, J. L., Byers, F. W., Daniels, J. S., Emmitte, K. A., Conn, P. J., & Lindsley, C. W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400439t · Cited by 57
Self-citation
Regulation of G Protein-Coupled Receptors by Allosteric Ligands
Lane, J. R., Abdul‐Ridha, A., & Canals, M. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400005t · Cited by 57
Mechanistic Insights into Allosteric Structure-Function Relationships at the M1 Muscarinic Acetylcholine Receptor
Abdul‐Ridha, A., Lane, J. R., Mistry, S. N., López, L., Sexton, P. M., Scammells, P. J., Christopoulos, A., & Canals, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.604967 · Cited by 56
Self-citation
Revealing the Allosterome: Systematic Identification of Metabolite–Protein Interactions
Orsak, T. W., Smith, T., Eckert, D., Lindsley, J. E., Borges, C. R., & Rutter, J. P. (2011) · Biochemistry · doi:10.1021/bi201313s · Cited by 56
Diverse Effects on M 1 Signaling and Adverse Effect Liability within a Series of M 1 Ago-PAMs
Rook, J. M., Abe, M., Cho, H. P., Nance, K. D., Luscombe, V. B., Adams, J. J., Dickerson, J. W., Remke, D. H., García-Barrantes, P. M., Engers, D. W., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00429 · Cited by 56
Self-citation
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154
Gould, R. W., Grannan, M. D., Gunter, B. W., Ball, J., Bubser, M., Bridges, T. M., Wess, J., Wood, M. W., Brandon, N. J., Duggan, M. E., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.013 · Cited by 54
Self-citation
Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications
Caprioli, D., Justinova, Z., Venniro, M., & Shaham, Y. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.018 · Cited by 55
Programmable allosteric DNA regulations for molecular networks and nanomachines
Zhang, C., Ma, X., Zheng, X., Ke, Y., Chen, K., Liu, D., Lu, Z., Yang, J., & Yan, H. (2022) · Science Advances · doi:10.1126/sciadv.abl4589 · Cited by 55
Conformational ensembles, signal transduction and residue hot spots: application to drug discovery.
Acuner, S. E., Gürsoy, A., Keskin, Ö., & Nussinov, R. (2010) · PubMed · Cited by 55
The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders
Peterlik, D., Flor, P. J., & Uschold‐Schmidt, N. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150515234920 · Cited by 56
All muscarinic acetylcholine receptors (M1-M5) are expressed in murine brain microvascular endothelium
Radu, B. M., Osculati, A. M. M., Suku, E., Banciu, A., Tsenov, G., Merigo, F., Chio, M. D., Banciu, D. D., Tognoli, C., Kačer, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05384-z · Cited by 55
TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects
Sako, Y., Kurimoto, E., Mandai, T., Suzuki, A., Tanaka, M., Suzuki, M., Shimizu, Y., Yamada, M., & Kimura, H. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0168-8 · Cited by 55
Allosteric modulation as a unifying mechanism for receptor function and regulation
Changeux, J., & Christopoulos, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12959 · Cited by 59
Self-citation

Authors: Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W.
Affiliations: Monash University (AU)
Vanderbilt University (US)
ORCID: Christopoulos, Arthur
Lindsley, Craig W.
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2009-01
Volume: 8
Issue: 1
Pages: 41-54
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd2760
PMC: PMC2907734
OpenAlex: W2003736358
Cited by: 1,063
References: 139
Citations by year: 2026: 30 · 2025: 46 · 2024: 37 · 2023: 25 · 2022: 48 · 2021: 51 · 2020: 44 · 2019: 58 · 2018: 57 · 2017: 68 · 2016: 64 · 2015: 67 · 2014: 69 · 2013: 80 · 2012: 75
FWCI: 6.60
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Mental Health (R01MH073676, R01MH074953, R01MH062646)
National Institute on Drug Abuse (R01DA023926)
National Institute of Neurological Disorders and Stroke (R01NS031373)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: G protein-coupled receptors, allosteric modulators, allosteric site, orthosteric ligands, mental illness, neurological disorders, CNS drug discovery, receptor selectivity, novel therapeutic agents
MeSH terms: Allosteric Regulation, Animals, Central Nervous System Diseases, Drug Evaluation, Preclinical, Humans, Ligands, Drug Design, Receptors, G-Protein-Coupled

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks